News
The University of Glasgow, in partnership with the University of Stirling, the University of Edinburgh, and University College London, has launch ...
Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s dise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback